HonorHealth Research Institute Jun 16 2025 The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those with a rare muscle-weakness disease known as Myasthenia Gravis. In an odd medical twist, this auto-immune disease - in which antibodies interfere with the connection between nerves and muscles - most often strikes young women in their 20s and 30s, and older men in their 60s and 70s, though